Cost effectiveness of personalized therapy for first-line treatment of stage IV and recurrent incurable adenocarcinoma of the lung

Journal of Oncology Practice

Volumn 8, Issue 5, 2012, Pages 267-274

  Handorf, Elizabeth A ^a   McElligott, Sean ^a   Vachani, Anil ^a   Langer, Corey J ^a   Demeter, Mirar Bristol ^a   Armstrong, Katrina ^a   Asch, David A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ONDANSETRON; PACLITAXEL; PEMETREXED;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; FEBRILE NEUTROPENIA; FEMALE; GENE MUTATION; HEALTH STATUS; HOSPITALIZATION COST; HUMAN; LUNG ADENOCARCINOMA; LUNG BIOPSY; MALE; MEDICAID; MEDICAL FEE; MEDICARE; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT CANCER; REIMBURSEMENT; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS; TRANSTHORACIC BIOPSY; VOMITING;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GENETIC TESTING; GLUTAMATES; GUANINE; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM STAGING; PACLITAXEL; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; UNITED STATES;

EID: 84872849132     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000502     Document Type: Article

References (46)

1. National Cancer Institute: Costs of cancer care. http://progressreport. cancer-gov/doc-detail.asp?pid=1&did=2007&chid=75&coid=726&mid=
2. National Cancer Institute: SEER cancer statistics review 1975-2008. http://seer.cancer.gov/csr/1975-2008/index.html
3. National Cancer Institute: SEER fast stats. http://seer.cancer.gov/ faststats/selections.php?#Output
4. Douillard JY, Shepherd FA, Hirsh V, et al: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: Data from the randomized phase III INTEREST trial. J Clin Oncol 28:744-752, 2010
5. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388, 2010
6. Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128, 2010
7. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
8. National Cancer Institute: Phase III study (Tarceva) vs. chemotherapy to treat advanced non-small-cell lung cancer (NSCLC) in patients with mutations in the TK domain of EGFR: NCT00446225. http://clinicaltrials.gov/ct2/show/ NCT00446225?term=NCT00446225&rank=1
9. Rosell R, Moran T, Queralt C, et al: Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967, 2009
10. Sequist LV, Martins RG, Spigel D, et al: First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449, 2008
11. Zhou C, Wu YL, Chen GY, et al: Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine(GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activatingmutations. Presented at the European Society for Medical Oncology Congress, Milan, Italy, October 8-12, 2010
12. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
13. National Comprehensive Cancer Network: Clinical practice guidelines in oncology: Non-small-cell lung cancer. www.nccn.org/professionals/physician-gls/ pdf/nscl.pdf
14. Pirker R: Stage IV: Targeted therapy as first line treatment - Yes. Presented at the 2nd European Lung Cancer Conference, Geneva, Switzerland, April 28-May 1, 2010
15. Scagliotti GV: Stage IV: Targeted therapy as first line treatment - No. Presented at the 2nd European Lung Cancer Conference, Geneva, Switzerland, April 28-May 1, 2010
16. Carlson JJ, Garrison LP, Ramsey SD, et al: The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 12:20-27, 2009
17. de Lima Lopes G Jr, Segel JE, Tan DS, et al: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 118:1032-1039, 2011
18. Shigematsu H, Lin L, Takahashi T, et al: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346, 2005
19. Klein R, Muehlenbein C, Liepa AM, et al: Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 4:1404-1414, 2009
20. Patel JD, Hensing TA, Rademaker A, et al: Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27:3284-3289, 2009
21. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
22. Zinner RG, Fossella FV, Gladish GW, et al: Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104:2449-2456, 2005
23. Scagliotti GV, Kortsik C, Dark GG, et al: Pemetrexed combined with oxalip-latin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 11:690-696, 2005
24. Nafees B, Stafford M, Gavriel S, et al: Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 6:84, 2008
25. Johnson BE, Ryan AJ, Heymach J, et al: Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC. J Clin Oncol 28:542s, 2010 (suppl; abstr 7516)
26. Tsao MS, Sakurada A, Cutz JC, et al: Erlotinib in lung cancer: Molecular and clinical predictors of outcome. N Engl J Med 353:133-144, 2005
27. Eberhardt R, Anantham D, Ernst A, et al: Multimodality bronchoscopic diagnosis of peripheral lung lesions: A randomized controlled trial. Am J Respir Crit Care Med 176:36-41, 2007
28. Facciolongo N, Patelli M, Gasparini S, et al: Incidence of complications in bronchoscopy: Multicentre prospective study of 20,986 bronchoscopies. Monaldi Arch Chest Dis 71:8-14, 2009
29. Geraghty PR, Kee ST, McFarlane G, et al: CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: Needle size and pneumothorax rate. Radiology 229:475-481, 2003
30. Hergott CA, Tremblay A: Role of bronchoscopy in the evaluation of solitary pulmonary nodules. Clin Chest Med 31:49-63, 2010
31. Genentech: Tarceva prescribing information. www.gene.com/gene/prod-ucts/ information/pdf/tarceva-prescribing.pdf
32. Malhotra B, Evans T, Weiss J, et al: Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: A single institution experience. Clin Lung Cancer 11:192-197, 2010
33. Drugstore.com: Online pharmacy. www.drugstore.com/prescriptions/ qxc10663
34. Centers for Medicare and Medicaid Services: Medicare Part B drug average sales price, April 2010. http://www.cms.gov/McrPartBDrugAvgSalesPrice/01a19- 2010aspfiles.asp#TopOfPage
35. Centers for Medicare and Medicaid Services: FY 2009 physician fee schedule. https://www.cms.gov/apps/physician-fee-schedule/search/search- criteria.aspx
36. Centers for Medicare and Medicaid Services: FY 2009 inpatient prospective payment system final rule. www.cms.gov/AcuteInpatientPPS/IPPS2009/ list.asp#TopOfPage
37. Yabroff KR, Lamont EB, Mariotto A, et al: Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 100:630-641, 2008
38. Bureau of Labor and Statistics: Inflation and prices. http://data.bls.gov
39. Willan AR, Briggs AH: Statistical analysis of cost-effectiveness data. Chichester, England, John Wiley, 2006
40. National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). http://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
41. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
42. Mosteller RD: Simplified calculation of body-surface area. N Engl J Med 317:1098, 1987
43. Bonomi P, Kim K, Fairclough D, et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623-631, 2000
44. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
45. World Health Organization: CHOosing Interventions that are Cost Effective (WHO-CHOICE). www.who.int/choice/costs/CER-levels/en/index.html
46. Appleby J, Devlin N, Parkin D: NICE's cost effectiveness threshold. BMJ 335:358-359, 2007